AbCellera Biologics Inc.

AbCellera runs an antibody-discovery engine, it uses its platform to find and optimize therapeutic antibodies, earning milestones and royalties from drug-developer partners while building its own programs.

Ticker

ABCL

Company

AbCellera Biologics Inc.

Exchange

Nasdaq

Listing

listed

Sector

Biotech / Antibody Discovery Platform

On X, $ABCL is framed as a shovels-not-gold platform bet: you are not buying one drug, you are buying the factory that discovers many. The upside is diversified across dozens of partnered shots inside a single ticker, including programs not yet on anyone's radar.

• AbCellera Biologics is listed on Nasdaq under the ticker ABCL and files reports with the U.S. SEC.S1
• AbCellera runs an antibody-discovery platform: it finds and engineers therapeutic antibodies for drug-developer partners, earning research payments, milestones and royalties, while also advancing its own clinical programs.S2
• In fiscal year 2025 (ended December 31, 2025) AbCellera reported total revenue of about $75.1 million, up from $28.8 million in 2024, and a net loss of about $146.4 million, or $(0.49) per share.S2
• As of December 31, 2025 AbCellera reported $533.8 million of cash, cash equivalents and marketable securities, comprising $128.5 million of cash and equivalents and $405.3 million of marketable securities. Adding restricted cash and available non-dilutive government funding, the company describes approximately $700 million of available liquidity.S2
• At June 30, 2026 the position was $540.1 million, comprising $120.1 million of cash and equivalents and $420.0 million of marketable securities, an increase of $6.3 million over the half year. AbCellera attributes the increase to the full receipt of a $36.0 million litigation settlement and a $56.0 million upfront payment for next-generation T-cell engaging multispecific antibodies, partly offset by operating cash use.S3
• Q2 2026 total revenue fell to $4.050 million from $17.084 million a year earlier, and first-half revenue fell to $12.362 million from $21.320 million. The company attributes the decline to licensing revenue recognised in the second quarter of 2025 and to the timing of research work. Licensing and royalty revenue alone fell from $10.445 million to $0.149 million in the quarter.S3
• Spending shifted rather than fell. Q2 research and development rose 17% to $45.987 million as ABCL575 and ABCL635 progressed in the clinic, while sales, general and administrative expense fell to $13.850 million from $21.986 million. Total operating expenses were roughly flat at $66.827 million.S3
• The Q2 2026 net loss widened to $55.427 million from $34.727 million a year earlier, and the first-half net loss widened to $98.592 million from $80.348 million. First-half cash used in operations was only $7.600 million against $43.958 million a year earlier, because the settlement and upfront receipts landed inside the period.S3
• AbCellera and its partners have advanced a cumulative total of 19 molecules into the clinic as of year-end 2025, up from 16 a year earlier.S2

• narrativePlatform-economics framing: a discovery engine spreads a clinical bet across many partnered shots, so single-readout risk matters less than for a one-asset biotech.
• narrativeBull case as it circulates: once one partnered asset de-risks the platform, the market reprices the whole engine rather than a single molecule.

• ▸AbCellera is a clinical-stage company that ran a roughly $146.4 million net loss in 2025 and depends on partner programs advancing. Clinical and regulatory execution on its own pipeline, continued cash burn and potential future dilution all apply.S2
• ▸Platform revenue is lumpy in both directions. Q2 2026 revenue was less than a quarter of the prior-year quarter because a single licensing recognition sat in the 2025 comparison. A quarter of platform revenue says little on its own, which cuts against reading any single quarter as a trend.S3
• ▸The first-half cash burn of $7.6 million looks mild but is flattered by two one-time receipts totalling $92.0 million. Underlying operating spending rose, with Q2 research and development up 17% and the quarterly net loss widening by $20.7 million year over year.S3

Antibody discovery platform

— A technology stack that searches for and engineers antibodies (the proteins the immune system uses to target disease) faster and across more targets than traditional methods.

Royalty and milestone model

— Instead of selling its own drug, the company earns payments when partners hit development steps and a share of future sales.